KR20230035600A - Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도 - Google Patents

Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도 Download PDF

Info

Publication number
KR20230035600A
KR20230035600A KR1020237003921A KR20237003921A KR20230035600A KR 20230035600 A KR20230035600 A KR 20230035600A KR 1020237003921 A KR1020237003921 A KR 1020237003921A KR 20237003921 A KR20237003921 A KR 20237003921A KR 20230035600 A KR20230035600 A KR 20230035600A
Authority
KR
South Korea
Prior art keywords
ghrh
trans
hexenoyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003921A
Other languages
English (en)
Korean (ko)
Inventor
크리스티안 마르솔레
키릴 신젤
다이앤 포트빈
Original Assignee
쎄러테크놀로지스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쎄러테크놀로지스 인코포레이티드 filed Critical 쎄러테크놀로지스 인코포레이티드
Publication of KR20230035600A publication Critical patent/KR20230035600A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237003921A 2020-07-05 2021-06-30 Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도 Pending KR20230035600A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063048167P 2020-07-05 2020-07-05
US63/048,167 2020-07-05
PCT/CA2021/050904 WO2022006657A1 (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Publications (1)

Publication Number Publication Date
KR20230035600A true KR20230035600A (ko) 2023-03-14

Family

ID=79553399

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003921A Pending KR20230035600A (ko) 2020-07-05 2021-06-30 Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도

Country Status (9)

Country Link
US (1) US20230270865A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175661A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533498A (cg-RX-API-DMAC7.html)
KR (1) KR20230035600A (cg-RX-API-DMAC7.html)
CN (1) CN115884783A (cg-RX-API-DMAC7.html)
AU (1) AU2021306736A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183299A1 (cg-RX-API-DMAC7.html)
IL (1) IL298991A (cg-RX-API-DMAC7.html)
WO (1) WO2022006657A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
MX2009010675A (es) * 2007-04-04 2009-10-23 Theratechnologies Inc Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20200297817A1 (en) * 2019-03-22 2020-09-24 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
CA3037757A1 (en) * 2019-03-22 2020-09-22 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
WO2020205498A1 (en) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease

Also Published As

Publication number Publication date
AU2021306736A1 (en) 2023-01-19
JP2023533498A (ja) 2023-08-03
EP4175661A1 (en) 2023-05-10
US20230270865A1 (en) 2023-08-31
CN115884783A (zh) 2023-03-31
IL298991A (en) 2023-02-01
EP4175661A4 (en) 2024-08-07
WO2022006657A1 (en) 2022-01-13
CA3183299A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
ES2405994T3 (es) Soluciones estabilizadas de teriparatide
US4548922A (en) Drug administration
JP5042312B2 (ja) Hghを含む経口送達用医薬組成物
EP3912639A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
EP3528828B1 (en) Terlipressin composition for use in treating ascites
SK119895A3 (en) Pharmaceutical composition containing lipophilic drugs
BRPI0616300A2 (pt) formulaÇço aquosa de hfsh
JP2010523501A (ja) Ghrh分子の医薬製剤
EP2961432A1 (en) Formulations of growth hormone releasing factor (grf) molecules with improved stability
KR100419558B1 (ko) 생리적으로활성인펩티드를함유하는질내투여제제
BG64668B1 (bg) Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична среда
US20220378880A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
KR890000907B1 (ko) 안정한 현탁액 제조용 고체 약물 제형의 제조방법
US6623732B1 (en) Pharmaceutical formulation for nasal administration
JP3555961B2 (ja) 安定なペプチド医薬組成物
US20230270865A1 (en) Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
AU778208C (en) GRF-containing lyophilized pharmaceutical compositions
CA3037757A1 (en) Pharmaceutical compositions of ghrh analogs and uses thereof
BR112020024399A2 (pt) composição líquida sem água e sistema para administração transmucosal oral de um ingrediente ativo através de uma composição líquida
RU2545915C1 (ru) Способ лечения хронического болевого синдрома
WO2005027960A1 (en) Liquid human growth hormone formulation containing polyethylene glycol
JP2810730B2 (ja) モチリン製剤
AU2005200879B2 (en) GRF-containing lyophilized pharmaceutical compositions
CN121604976A (zh) 用于增强黏膜渗透的组合物
JP2002515416A (ja) 経鼻投与用医薬製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240628

Comment text: Request for Examination of Application